• FDA grants Breakthrough Device Designation to Renalytix for its KidneyIntelX test, identifying it as a breakthrough technology for which no approved or cleared alternative exists and meeting the criteria of providing a more effective treatment or diagnosis of life-threatening or irreversibly debilitating human disease.


  • Renalytix published a manuscript outlining demonstrated performance of its machine learning algorithm which combines biomarkers and EHR data to predict progressing kidney disease.